Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/19/2009US20090075984 Materials and methods relating to protein aggregation in neurodegenerative disease
03/19/2009US20090075983 Novel Diazabicycloalkane Derivatives and Their Medical Use
03/19/2009US20090075982 Piperazine compounds
03/19/2009US20090075981 INHIBITORS OF p38
03/19/2009US20090075980 Pyrazolopyridines and Analogs Thereof
03/19/2009US20090075979 CETP Inhibitors
03/19/2009US20090075978 Substituted propiolic acid amides and their use for producing drugs
03/19/2009US20090075977 Deuterium-enriched mk0974
03/19/2009US20090075976 Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor
03/19/2009US20090075975 Arylsulfonamides and uses related thereto
03/19/2009US20090075974 Agent for prophylaxis and treatment of pancreatitis
03/19/2009US20090075973 Benzo-fused heterocycles
03/19/2009US20090075972 Use of Midostaurin for Treating Gastrointestinal Stromal Tumors
03/19/2009US20090075971 Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same
03/19/2009US20090075970 Thieno-and furo-pyrimidine modulators of the histamine H4 receptor
03/19/2009US20090075969 Deuterium-enriched doripenem
03/19/2009US20090075968 CETP inhibitors
03/19/2009US20090075967 Deuterium-enriched ceftriaxone
03/19/2009US20090075966 Deuterium-enriched tazobactam
03/19/2009US20090075965 Deuterium-enriched amoxicilin
03/19/2009US20090075964 Fragrance compositions and other compositions which contain naturally occurring substances found in corals
03/19/2009US20090075963 Transdermal hormone spray
03/19/2009US20090075962 Growth stimulant compositions
03/19/2009US20090075961 Testosterone Oral Dosage Formulations And Associated Methods
03/19/2009US20090075960 Method of treating gaucher disease
03/19/2009US20090075959 Deuterium-enriched ciclesonide
03/19/2009US20090075958 Clobetasol propionate shampoos for the treatment of seborrheic dermatitis of the scalp
03/19/2009US20090075957 Xanthohumol compositions and methods of using same
03/19/2009US20090075956 Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3
03/19/2009US20090075955 Therapeutic regimens for the treatment of immunoinflammatory disorders
03/19/2009US20090075954 Soft anticholinergic esters
03/19/2009US20090075953 Deuterium-enriched ed-71
03/19/2009US20090075952 Nitroderviatives as drugs for diseases having an inflammatory basis
03/19/2009US20090075951 Methods and Reagents for the Treatment of Inflammatory Disorders
03/19/2009US20090075950 Dosage Forms Containing A PPI, NSAID And A Buffer
03/19/2009US20090075949 such as dabigatran etexilate, rivaroxaban, Ximelagatran, bivalirudin, Apixaban
03/19/2009US20090075948 Compositions and methods for regulating cellular protection
03/19/2009US20090075947 Deuterium-enriched fospropofol
03/19/2009US20090075946 Novel triterpenic acid derivative and preparation for external application for skin comprising the same
03/19/2009US20090075945 Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
03/19/2009US20090075944 Deuterium-enriched ibandronate
03/19/2009US20090075943 Combretastatin Analogs with Tubulin Binding Activity
03/19/2009US20090075942 Deuterium-enriched fosamprenavir
03/19/2009US20090075941 Treating neoplasms
03/19/2009US20090075940 Deuterium-enriched risedronate
03/19/2009US20090075939 Novel HIV reverse transcriptase inhibitors
03/19/2009US20090075938 Treatment of duchenne muscular dystrophy
03/19/2009US20090075937 Lhrh antagonists for the treatment of lower urinary tract symptoms
03/19/2009US20090075936 Proteasome inhibitors and methods of using the same
03/19/2009US20090075933 Cytocompatible alginate gels
03/19/2009US20090075932 METHOD OF SELECTIVELY INHIBITING PKCiota
03/19/2009US20090075931 isotope exchanged capecitabine, used for the treatment of metastatic breast cancer; anticarcinogenic agents
03/19/2009US20090075930 for treating leukemia
03/19/2009US20090075929 Ig20 splice variants therapeutics for cancer
03/19/2009US20090075928 G-QUARTET OLIGONUCLEOTIDES THAT TARGET HYPOXIA-INDUCIBLE FACTOR 1-a (HIF1a )
03/19/2009US20090075927 Sweet taste receptors
03/19/2009US20090075926 Method for identifying and manipulating cells
03/19/2009US20090075925 Methods and Compositions Related to APOBEC-1 Expression
03/19/2009US20090075924 antisense therapy; for diagnosis and treatment of atherosclerosis, hypercholesterolemia, or coronary artery disease
03/19/2009US20090075923 Methods of treatment of renal disease
03/19/2009US20090075922 Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met
03/19/2009US20090075921 Bone/joint disease sensitivity gene and use thereof
03/19/2009US20090075920 Deuterium-enriched decitabine
03/19/2009US20090075919 Anti-neoplastic compositions comprising extracts of black cohosh
03/19/2009US20090075918 Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine
03/19/2009US20090075917 Deuterium-enriched telithromycin
03/19/2009US20090075916 Use of Macrolide Derivatives for Treating Acne
03/19/2009US20090075915 6,11-bicyclolides: bridged biaryl macrolide derivatives
03/19/2009US20090075914 Deuterium-enriched odiparcil
03/19/2009US20090075913 Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent
03/19/2009US20090075912 Use of Timosaponin BII in the Preparation Of A Medicament or Product for the Prevention and Treatment of Stroke
03/19/2009US20090075911 Ester Derivatives of Hyaluronic Acid for the Preparation of Hydrogel Materials by Photocuring
03/19/2009US20090075910 Deuterium-enriched fondaparinux
03/19/2009US20090075909 Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds
03/19/2009US20090075908 Agent For Strengthening Calcium Containing Tissue and Use Thereof
03/19/2009US20090075902 Inhibiting the signs of aging by inhibiting nf-kappa b activation
03/19/2009US20090075900 Therapeutic agent for motor neuron disease
03/19/2009US20090075889 Iren protein, its preparation and use
03/19/2009US20090075888 Cardiovascular and Brain Cell Therapy Using Intracellular Ryanodine Receptor Modulation by the Estrogen Receptor Beta
03/19/2009US20090075873 Gastrin compositions and formulations, and methods of use and preparation
03/19/2009US20090075868 Synthetic peptide materials for joint reconstruction, repair and cushioning
03/19/2009US20090075867 Triazine compounds and compositions thereof for the treatment of cancers
03/19/2009US20090075864 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
03/19/2009US20090075861 Systems and methods of removing and managing heavy metals
03/19/2009US20090075860 Transdermal absorption enhancer
03/19/2009US20090075842 Neoglycorandomization and digitoxin analogs
03/19/2009US20090075839 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigents and uses thereof
03/19/2009US20090075819 Indanyl- and Tetrahydronaphtyl-amino-thiourea Compounds for Combating Animal Pests
03/19/2009US20090075376 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
03/19/2009US20090075369 Angiostatin Fragments and Method of Use
03/19/2009US20090075327 Methods for improving secondary metabolite production in fungi
03/19/2009US20090075302 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090075279 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090075278 Compositions and methods for the diagnosis and treatment of tumor
03/19/2009US20090075268 Glycoprotein for use in the treatment of hearing loss defects; Inner Ear Supporting Cell Antigen (IESCA) reactive with an autoantibody associated with AISNHL
03/19/2009US20090074891 Combretum laurifolium mart. extract and methods of extracting and using such extract
03/19/2009US20090074890 Substituted Triazoles as Sodium Channel Blockers
03/19/2009US20090074887 For control of phytopathogenic fungi; synergistic
03/19/2009US20090074886 Gsk-3 inhibitors
03/19/2009US20090074885 Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells